BioPharma Dive November 20, 2024
Gwendolyn Wu

Pfizer will work with Ampersand Biomedicines and Montai Therapeutics to find drugs for lung cancer and obesity, adding to collaborations it formed with other Flagship startups earlier this year.

Dive Brief:

  • Pfizer will work with two more startups incubated by Flagship Pioneering, which on Wednesday announced that Montai Therapeutics and Ampersand Biomedicines would hunt for drug candidates under an existing collaboration with the pharmaceutical giant.
  • Montai aims to unearth new small molecule drugs for lung cancer, while Ampersand will help the pharma discover biologics for obesity. Flagship didn’t reveal financial terms for either deal, though a spokesperson said Pfizer will split R&D costs and has an option to license a program.
  • Both deals are products of an alliance Pfizer...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Why Walgreens Is Reportedly Considering a Private Equity Buyer
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
Why 2025 Could Be A Good Reimbursement Year For CVS And Walgreens
PBM reform dropped in Congress' funding package
2025 and Beyond: Key Trends to Watch in Pharmacy

Share This Article